Anhui Kedgene Biotechnology

Anhui Kedgene Biotechnology is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and advanced delivery systems. Headquartered in Hefei, the company was founded by a team of scientists from the University of Science and Technology of China (USTC) to commercialize innovative lipid nanoparticle (LNP) technology. Kedgene's platform focuses on the precise delivery of mRNA and gene-editing tools, such as CRISPR/Cas, to target tissues. Their current pipeline includes candidates for infectious disease vaccines, cancer immunotherapy, and treatments for rare genetic disorders. The company maintains an integrated R&D and pilot manufacturing facility to support its transition from discovery to clinical development. By leveraging its proprietary delivery materials, Kedgene aims to overcome the stability and targeting challenges associated with nucleic acid drugs.